NeuBase Therapeutics, Inc.NeuBase Therapeutics, Inc.NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪1.61 M‬USD
−9.7612USD
‪3.04 M‬
Beta (1Y)
1.20

About NeuBase Therapeutics, Inc.

CEO
Todd P. Branning
Headquarters
Pittsburgh
Founded
2009
ISIN
US64132K2015
FIGI
BBG000CB75J2
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of NBSE is 0.4300 USD — it has decreased by 0.83% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeuBase Therapeutics, Inc. stocks are traded under the ticker NBSE.
NeuBase Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
NBSE stock is 5.76% volatile and has beta coefficient of 1.20. Check out the list of the most volatile stocks — is NeuBase Therapeutics, Inc. there?
NBSE earnings for the last quarter are −2.40 USD per share, whereas the estimation was −2.30 USD resulting in a −4.35% surprise. The estimated earnings for the next quarter are −2.10 USD per share. See more details about NeuBase Therapeutics, Inc. earnings.
Yes, you can track NeuBase Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
NBSE stock has risen by 4.88% compared to the previous week, the month change is a 60.19% fall, over the last year NeuBase Therapeutics, Inc. has showed a 86.73% decrease.
NBSE net income for the last quarter is ‪−1.82 M‬ USD, while the quarter before that showed ‪−3.45 M‬ USD of net income which accounts for 47.17% change. Track more NeuBase Therapeutics, Inc. financial stats to get the full picture.
Today NeuBase Therapeutics, Inc. has the market capitalization of ‪1.61 M‬, it has decreased by 4.35% over the last week.
No, NBSE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NBSE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeuBase Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
NBSE reached its all-time high on Mar 17, 2014 with the price of 8000.0000 USD, and its all-time low was 0.3900 USD and was reached on Apr 5, 2024.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeuBase Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeuBase Therapeutics, Inc. stock shows the sell signal. See more of NeuBase Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.